30 results on '"Kamat, A.M."'
Search Results
2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
3. Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder
4. A0863 - Urachal (U) and Non-Urachal (NU) Adenocarcinomas (adenoCA) of the bladder: A comparative Comprehensive Genomic Profiling (CGP) study
5. A0743 - Impact of systemic therapy in clinical T1 small-cell neuroendocrine carcinoma of the bladder
6. A0739 - Challenging the paradigm of BCG unresponsive bladder cancer: Does additional BCG have an effect?
7. A0742 - The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance
8. A0583 - Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial
9. A0328 - Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress)
10. A0151 - Management, surveillance patterns, and costs associated with low-grade Papillary (Ta) non-muscle invasive bladder cancer
11. A0147 - The updated EAU prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin
12. P144 - Accuracy of novel urinary biomarker tests for diagnosis and surveillance of NMIBC: A systematic review, diagnostic test accuracy and network meta-analyses
13. 718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
14. P0745 - Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
15. P0746 - Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
16. P0720 - All HG NMIBC is high risk: BCG response in HG Ta lesions
17. PCN62 DISEASE BURDEN ASSOCIATED WITH PROGRESSION IN PATIENTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER RECEIVING BLADDER PRESERVING THERAPIES AFTER ADEQUATE BCG INDUCTION: A SEER-MEDICARE DATABASE STUDY
18. PCN42 TREATMENT PATTERNS AND SURVIVAL AMONG PATIENTS WITH BCG UNRESPONSIVE HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER: AN ASSESSMENT OF THE SEER-MEDICARE DATA
19. 924P - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
20. 916P - Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)
21. Outcomes of radical cystectomy following implementation of enhanced recovery after surgery protocols: A systematic review
22. 849TiP - Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
23. 433 EFFICACY AND SAFETY OF MYCOBACTERIAL CELL WALL DNA COMPLEX IN THE TREATMENT OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER AT HIGH RISK OF PROGRESSION AND WHO ARE REFRACTORY TO BCG
24. 189 PERIOPERATIVE OUTCOMES OF LAPAROSCOPIC RADICAL NEPHROURETERECTOMYAND REGIONAL LYMPHADENECTOMY IN PATIENTS WITH UPPER URINARY TRACT UROTHELIAL CARCINOMA AFTER NEOADJUVANT CHEMOTHERAPY
25. 323 INTERNATIONAL VALIDATION OF THE PROGNOSTIC VALUE OF LYMPHOVASCULAR INVASION IN RADICAL CYSTECTOMY PATIENTS
26. A1004 - International opinions on grading of urothelial carcinoma: A survey among European Association of Urology and International Society of Urological Pathology members.
27. A0722 - Bacillus calmette-guerin vs immediate radical cystectomy in eau defined very high-risk non-muscle invasive bladder cancer patients.
28. A0611 - Implementing the Active Surveillance (AS) follow-up schedule for low-grade Non- Muscle-Invasive Bladder Cancer (NMIBC) tumors.
29. A0607 - T1 substaging is associated with worse oncological outcomes for patients treated with Bacillus Calmette-Guerin or immediate radical cystectomy.
30. A0605 - Association of age with non-muscle-invasive bladder cancer: A biological basis for epidemiological disparities?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.